Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis
- PMID: 23287128
- PMCID: PMC3573602
Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis
Abstract
Background & objectives: Pyrazinamide is an essential component of first line anti-tuberculosis regimen as well as most of the second line regimens. This drug has a unique sterilizing activity against Mycobacterium tuberculosis. Its unique role in tuberculosis treatment has lead to the search and development of its structural analogues. One such analogue is 5-chloro-pyrazinamide (5-Cl-PZA) that has been tested under in vitro conditions against M. tuberculosis. The present study was designed with an aim to assess the activity of 5-Cl-PZA, alone and in combination with first-line drugs, against murine tuberculosis.
Methods: The minimum inhibitory concentration (MIC) of 5-Cl-PZA in Middlebrook 7H9 broth (neutral pH) and the inhibitory titre of serum from mice that received a 300 mg/kg oral dose of 5-Cl-PZA 30 min before cardiac puncture were determined. To test the tolerability of orally administered 5-Cl-PZA, uninfected mice received doses up to 300 mg/kg for 2 wk. Four weeks after low-dose aerosol infection either with M. tuberculosis or M. bovis, mice were treated 5 days/wk with 5-Cl-PZA, at doses ranging from 37.5 to 150 mg/kg, either alone or in combination with isoniazid and rifampicin. Antimicrobial activity was assessed by colony-forming unit counts in lungs after 4 and 8 wk of treatment.
Results: The MIC of 5-Cl-PZA against M. tuberculosis was between 12.5 and 25 μg/ml and the serum inhibitory titre was 1:4. Under the same experimental conditions, the MIC of pyrazinamide was >100 μg/ml and mouse serum had no inhibitory activity after a 300 mg/kg dose; 5-Cl-PZA was well tolerated in uninfected and infected mice up to 300 and 150 mg/kg, respectively. While PZA alone and in combination exhibited its usual antimicrobial activity in mice infected with M. tuberculosis and no activity in mice infected with M. bovis, 5-Cl-PZA exhibited antimicrobial activity neither in mice infected with M. tuberculosis nor in mice infected with M. bovis.
Interpretation & conclusion: Our findings showed that 5-Cl-PZA at doses up to 150 mg/kg was not active in chronic murine TB model. Further studies need to be done to understand the mechanism and mode of inactivation in murine model of tuberculosis.
Similar articles
-
Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.J Med Microbiol. 2007 Aug;56(Pt 8):1047-1051. doi: 10.1099/jmm.0.47058-0. J Med Microbiol. 2007. PMID: 17644711
-
Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.Antimicrob Agents Chemother. 2009 Oct;53(10):4178-84. doi: 10.1128/AAC.00830-09. Epub 2009 Jul 20. Antimicrob Agents Chemother. 2009. PMID: 19620331 Free PMC article.
-
High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.Antimicrob Agents Chemother. 2016 Jun 20;60(7):4197-205. doi: 10.1128/AAC.03085-15. Print 2016 Jul. Antimicrob Agents Chemother. 2016. PMID: 27139472 Free PMC article.
-
Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.Trends Pharmacol Sci. 2019 Dec;40(12):930-940. doi: 10.1016/j.tips.2019.10.005. Epub 2019 Nov 6. Trends Pharmacol Sci. 2019. PMID: 31704175 Free PMC article. Review.
-
Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update.Adv Med Sci. 2016 Mar;61(1):63-71. doi: 10.1016/j.advms.2015.09.007. Epub 2015 Oct 1. Adv Med Sci. 2016. PMID: 26521205 Review.
Cited by
-
Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.Antimicrob Agents Chemother. 2015 Nov 16;60(2):735-43. doi: 10.1128/AAC.01370-15. Print 2016 Feb. Antimicrob Agents Chemother. 2015. PMID: 26574016 Free PMC article.
-
Mechanisms of Pyrazinamide Action and Resistance.Microbiol Spectr. 2013;2(4):1-12. doi: 10.1128/microbiolspec.MGM2-0023-2013. Microbiol Spectr. 2013. PMID: 25530919 Free PMC article.
-
Synthesis and in vitro evaluation of substituted 3-cinnamoyl-4-hydroxy-pyran-2-one (CHP) in pursuit of new potential antituberculosis agents.Medchemcomm. 2017 Dec 6;9(1):165-172. doi: 10.1039/c7md00366h. eCollection 2018 Jan 1. Medchemcomm. 2017. PMID: 30108910 Free PMC article.
-
The biodistribution of 5-[18F]fluoropyrazinamide in Mycobacterium tuberculosis-infected mice determined by positron emission tomography.PLoS One. 2017 Feb 2;12(2):e0170871. doi: 10.1371/journal.pone.0170871. eCollection 2017. PLoS One. 2017. PMID: 28151985 Free PMC article.
-
Mechanism of the dual action self-potentiating antitubercular drug morphazinamide.PNAS Nexus. 2025 Jul 29;4(8):pgaf242. doi: 10.1093/pnasnexus/pgaf242. eCollection 2025 Aug. PNAS Nexus. 2025. PMID: 40799345 Free PMC article.
References
-
- Gu P, Constantino L, Zhang Y. Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide. J Med Microbiol. 2008;57:1129–34. - PubMed
-
- Wade MM, Zhang Y. Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J Med Microbiol. 2004;53:769–73. - PubMed
-
- Steele MA, Des Prez RM. The role of pyrazinamide in tuberculosis chemotherapy. Chest. 1988;94:845–50. - PubMed
-
- Konno K, Nagayama H, Oka S. Nicotinamidase in mycobacteria: a method for distinguishing bovine type tubercle bacilli from other mycobacteria. Nature. 1959;184:1743–4. - PubMed
-
- Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis. 2003;7:6–21. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical